Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

VYNE Therapeutics (VYNE) Total Non-Current Liabilities (2016 - 2024)

VYNE Therapeutics (VYNE) has disclosed Total Non-Current Liabilities for 9 consecutive years, with $25000.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Total Non-Current Liabilities fell 99.67% year-over-year to $25000.0, compared with a TTM value of $25000.0 through Jun 2024, down 99.67%, and an annual FY2023 reading of $1.4 million, changed N/A over the prior year.
  • Total Non-Current Liabilities was $25000.0 for Q2 2024 at VYNE Therapeutics, down from $1.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $58.6 million in Q2 2021 and bottomed at $25000.0 in Q2 2024.
  • Average Total Non-Current Liabilities over 5 years is $20.3 million, with a median of $8.5 million recorded in 2022.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 67.15% in 2021, then tumbled 99.67% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $34.5 million in 2020, then crashed by 36.27% to $22.0 million in 2021, then tumbled by 69.83% to $6.6 million in 2022, then crashed by 78.71% to $1.4 million in 2023, then tumbled by 98.23% to $25000.0 in 2024.
  • Business Quant data shows Total Non-Current Liabilities for VYNE at $25000.0 in Q2 2024, $1.4 million in Q1 2024, and $1.4 million in Q4 2023.